NEW YORK, Dec. 18, 2017 —
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on ONVO, BEAT, BRKR, and PKI which is a click away at http://www.wallstequities.com/registration. As access to health care expands around the world, the need for diagnostic and research laboratory services will also increase, according to a First Research report. Growth in the industry is impacted by aging populations and rising demand for preventive care and personalized medical treatments, the report further noted. Ahead of today's trading session, WallStEquities.com presents for assessment the following stocks in the Medical Laboratories and Research industry: Organovo Holdings Inc. (NASDAQ: ONVO), BioTelemetry Inc. (NASDAQ: BEAT), Bruker Corp. (NASDAQ: BRKR), and PerkinElmer Inc. (NYSE: PKI). With Wall St. Equities' free research reports get an edge over stock markets, sign up now at: http://www.wallstequities.com/registration
San Diego, California headquartered Organovo Holdings Inc.'s stock rose 2.17%, finishing last Friday's trading session at $1.41. A total volume of 4.35 million shares was traded, which was above their three months average volume of 1.31 million shares. The Company's shares have gained 1.44% in the last month. The stock is trading below its 50-day moving average by 8.28%. Additionally, shares of Organovo, which designs and creates functional and 3D human tissues for use in medical research and therapeutic applications, have a Relative Strength Index (RSI) of 45.78. Our free and thorough report on ONVO awaits you at: http://www.wallstequities.com/registration/?symbol=ONVO
Shares in Malvern, Pennsylvania headquartered BioTelemetry Inc. ended at $29.95, up 3.10% from the last trading session. The stock recorded a trading volume of 1.22 million shares, which was above its three months average volume of 636,990 shares. The Company's shares have advanced 24.02% in the past month and 34.00% since the start of this year. The stock is trading 5.82% above its 50-day moving average. Moreover, shares of BioTelemetry, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, have an RSI of 62.49.
On November 30th, 2017, BioTelemetry announced a partnership with Apple to provide cardiac monitoring services, in conjunction with the Apple Heart Study. The study, which launched that day, is expected to discover undiagnosed irregular heart rhythms, such as atrial fibrillation, using the Apple Watch and the dedicated “Apple Heart Study” App. BEAT's complimentary research coverage is a few simple steps away at: http://www.wallstequities.com/registration/?symbol=BEAT
On Friday, shares in Billerica, Massachusetts headquartered Bruker Corp. recorded a trading volume of 713,402 shares, which was above their three months average volume of 521,860 shares. The stock climbed 2.15%, closing the day at $34.63. The Company's shares have gained 6.92% in the last one month, 14.97% over the previous three months, and 63.50% on an YTD basis. The stock is trading 6.26% above its 50-day moving average and 22.64% above its 200-day moving average. Additionally, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 57.80.
On December 13th, 2017, Bruker and The Metropolitan Museum of Art (The Met) announced a ten-year partnership to advance novel analytical technologies and methods in the field of cultural heritage science even further. With this new ambitious partnership, the duo will focus on advanced mass spectrometry instrumentation, as well as x-ray diffraction, and Raman imaging, adding state-of-the-art technology to the impressive array of scientific tools already in place at The Met. Register for your free research report on BRKR at: http://www.wallstequities.com/registration/?symbol=BRKR
At the close of trading on Friday, shares in Waltham, Massachusetts headquartered PerkinElmer Inc. recorded a trading volume of 1.14 million shares, which was higher than their three months average volume of 609,410 shares. The stock finished the session 1.84% higher at $72.13. The Company's shares have gained 1.41% in the past month, 3.81% in the previous three months, and 38.31% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.77% and 10.00%, respectively. Furthermore, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 54.90. Wall St. Equities' downloadable research report on PKI available at: http://www.wallstequities.com/registration/?symbol=PKI
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Latest posts by Brad Bennett (see all)
- HARDCAR's Security Division Hires Mr. Stephen 'Dodie' Petagna as President of Operations - February 21, 2018
- Nominees For 25th Annual NAMIC Vision Awards - February 21, 2018
- Kaya Fest Adds Ms. Lauryn Hill to Star-Studded Line-Up - February 21, 2018